AdaptHealth (AHCO) Q4 2023: Sleep Resupply Census Hits 1.55 Million, Driving Margin Expansion
AdaptHealth ended 2023 with record sleep resupply volumes and a meaningful margin lift, propelled by operational discipline and digital process gains. The company’s non-acquired growth and cash flow conversion outperformed, even as diabetes remains a work in progress and reimbursement headwinds loom for 2024. Management’s focus on cost-out, technology leverage, and strategic partnerships signals a multi-pronged approach to sustaining growth and deleveraging in a volatile payer environment.
Summary
- Sleep Resupply Expansion: Patient adherence and digital reordering propelled record volumes and operational leverage.
- Cost and Cash Flow Gains: Margin and free cash flow outpaced revenue as technology and CapEx discipline took hold.
- Diabetes and Payer Shifts: Segment remains pressured, but salesforce expansion and pharmacy channel ramp are underway for 2024 recovery.
Business Overview
AdaptHealth is a leading provider of home medical equipment and related services, specializing in sleep therapy, respiratory care, and diabetes management. The company generates revenue through equipment sales, rentals, resupply services, and capitated agreements with payers such as Humana. Major segments include Sleep (CPAP and supplies), Respiratory (oxygen and ventilation), Diabetes (continuous glucose monitors and pumps), and a diverse “Other” category (including e-commerce and hospice). AdaptHealth serves over 4 million patients annually, with a growing focus on digital engagement and adherence-driven recurring revenue.
Performance Analysis
AdaptHealth delivered broad-based growth in Q4, with net revenue up double digits and an adjusted EBITDA margin of 23.8%—a clear outperformance versus expectations. The standout driver was the Sleep segment, where resupply census reached 1.55 million patients, up 12% for the year, and electronic reordering surpassed 40% of orders. This digital shift not only improved patient experience but also unlocked operational efficiencies, compressing labor and OpEx costs.
The Respiratory segment also posted strong results, with oxygen census at an all-time high and continued market share gains. In contrast, Diabetes revenue declined, pressured by the ongoing shift from tubed to tubeless pumps and a migration to the pharmacy benefit channel. However, management’s doubling of the diabetes salesforce and a renewed focus on government payers laid groundwork for a second-half rebound. Notably, free cash flow conversion improved to 4.5% of revenue, exceeding the company’s target, while net leverage dropped to 3.16x, reflecting disciplined CapEx and working capital management.
- Sleep Resupply Momentum: Higher adherence and digital reordering drove record patient volumes and margin gains.
- Respiratory Share Capture: Oxygen census and non-invasive ventilation both grew, offsetting reimbursement headwinds.
- Diabetes Under Pressure: Segment revenue fell as pump mix shifted, but CGM government payer exposure rose to 79% of census.
Other revenue lines—including e-commerce, hospice, and new capitated contracts—provided incremental upside, with PMPM (per member per month) revenue from Humana contributing to sequential growth. The quarter also included a significant goodwill impairment and a legal settlement, both non-cash items, but underlying cash generation remained robust.
Executive Commentary
"Nearly 95% of the 2023 revenue growth was non-acquired. We finished the year with a very favorable quarter, driven by continued strength in our sleep and respiratory product lines and the expected improvement in our Humana contract."
Richard Barish, Chairman and Interim CEO
"Adjusted EBITDA grew 13% over that same period as we delivered on the cost management program that we announced in early 2023. Cash flow from operations of $480.7 million grew 28.6% over the prior year."
Jason Clemens, Chief Financial Officer
Strategic Positioning
1. Sleep and Respiratory Leadership
AdaptHealth further solidified its #1 position in U.S. CPAP and supplies, with adherence-focused sleep coaching and digital resupply driving share gains and recurring revenue. In respiratory, the company’s therapist-led approach enabled it to outpace industry growth and target category leadership.
2. Digital and Operational Efficiency
Technology investments—such as the proprietary claims editor and Oracle inventory digitalization—are compressing DSO (days sales outstanding) and CapEx intensity, freeing up cash for debt reduction and future growth. Electronic reordering and automated processes are lifting both patient satisfaction and operational margins.
3. Diabetes Turnaround and Pharmacy Channel Entry
The diabetes segment remains challenged by product mix and payer channel migration, but leadership has doubled the salesforce and is ramping up pharmacy channel capabilities. The focus is on government payers, where coverage expansions are expected to provide a tailwind in 2024 and beyond.
4. Payer Partnerships and Capitated Models
The Humana contract transition is nearly complete, with capitated PMPM revenue now a material contributor. Management is pursuing additional strategic relationships to drive incremental growth and diversify revenue streams.
5. Cautious Approach to GLP-1 Impact
Management sees no current adverse effect from GLP-1 drugs on core sleep and diabetes businesses, and is proactively focusing on adherence and market share to offset any future headwinds. Early data suggests GLP-1 users may even have higher CPAP adherence.
Key Considerations
AdaptHealth’s Q4 results demonstrate a business with strong core demand, disciplined execution, and a deliberate shift toward digital and recurring revenue streams. The company’s operational and strategic pivots are designed to buffer reimbursement volatility and drive sustainable cash flow.
Key Considerations:
- Digital Leverage in Sleep: Electronic reordering and adherence programs are driving both volume and margin expansion in the largest segment.
- Respiratory Upside: Market share gains and census growth position the segment for continued outperformance, even as reimbursement risk persists.
- Diabetes Execution Risk: The segment’s recovery depends on effective salesforce deployment and successful pharmacy channel ramp, with government payers as a key growth lever.
- CapEx and Working Capital Discipline: Technology-driven inventory and claims management are structurally improving free cash flow conversion and enabling deleveraging.
- Reimbursement Sensitivity: Expiration of the 75-25 rate relief creates a $25 million headwind in 2024, emphasizing the need for operational agility and strategic growth initiatives.
Risks
AdaptHealth faces notable risks from reimbursement changes, product mix shifts in diabetes, and the ongoing migration to pharmacy channels. The expiration of Medicare rate relief and continued pressure on pump revenues could weigh on results if not offset by operational gains or payer wins. GLP-1 adoption remains a long-term uncertainty, though management’s current data is reassuring. Regulatory and payer dynamics, including CMS rules and managed care behavior, will continue to impact growth visibility and margin structure.
Forward Outlook
For Q1 2024, AdaptHealth guided to:
- Revenue and adjusted EBITDA up approximately 3% year-over-year
- Free cash flow near zero, reflecting seasonal deductible resets and legal settlement outflows
For full-year 2024, management provided guidance:
- Revenue of $3.25 to $3.35 billion
- Adjusted EBITDA of $650 to $710 million
- Free cash flow of $150 to $180 million
Management emphasized:
- Mid-single digit sleep revenue growth, with resupply outpacing rentals
- Diabetes growth weighted to the second half as new salesforce and pharmacy initiatives ramp
- Continued focus on cost efficiency and debt reduction, targeting leverage below 3x by year-end
Takeaways
AdaptHealth’s quarter underscores the power of scale, digital engagement, and operational discipline in home medical equipment. The company’s ability to drive margin and cash flow ahead of revenue, while managing payer and product risk, positions it for resilient growth if execution on diabetes and strategic partnerships materializes.
- Recurring Revenue Engine: Sleep resupply and respiratory census are compounding, supported by digital and adherence initiatives that drive both growth and efficiency.
- Cash Flow and Leverage Improvement: Technology-enabled working capital gains and CapEx discipline are translating into higher free cash and rapid deleveraging.
- Watch Diabetes and Payer Mix: The pace of diabetes recovery, pharmacy channel penetration, and further payer partnerships will be pivotal for sustaining growth beyond 2024.
Conclusion
AdaptHealth’s Q4 capped a year of operational progress and strategic recalibration, with sleep and respiratory strength offsetting diabetes headwinds. The company’s digital and cost initiatives are gaining traction, but execution on diabetes and payer strategy will determine the next leg of growth and margin trajectory.
Industry Read-Through
AdaptHealth’s results signal that scale, digital engagement, and payer diversification are becoming table stakes in home medical equipment. The rapid growth in electronic resupply and adherence programs suggests that recurring revenue and patient stickiness will be key valuation drivers across the sector. Meanwhile, diabetes channel migration and reimbursement volatility highlight the need for operational agility and robust payer relationships. Competitors in sleep, respiratory, and diabetes should expect continued share battles and margin pressure, particularly as GLP-1 dynamics and pharmacy channel expansion reshape the landscape. The broader healthcare services industry can take note: technology-driven efficiency and payer mix management are now critical for sustainable growth and cash flow resilience.